Comparative Pharmacology
Head-to-head clinical analysis: FACTIVE versus MAXAQUIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FACTIVE versus MAXAQUIN.
FACTIVE vs MAXAQUIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gemifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
400 mg orally once daily for 5 days for acute exacerbation of chronic bronchitis; 400 mg orally once daily for 7 days for community-acquired pneumonia; 400 mg orally once daily for 5 days for acute bacterial sinusitis.
400 mg orally once daily for 5-10 days; for complicated urinary tract infections, 400 mg orally once daily for 10-14 days.
None Documented
None Documented
12.5 hours (range 10-16 hours), supporting once-daily dosing.
Terminal elimination half-life is approximately 12 hours (range 10-14 hours), supporting twice-daily dosing for systemic infections.
Renal excretion of unchanged drug accounts for approximately 61% of the administered dose; fecal elimination accounts for about 35%, with a minor biliary component.
Renal excretion of unchanged drug accounts for 70-80%; biliary/fecal elimination accounts for 20-30%.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic